Drug Profile
Mirodenafil - AriBio
Alternative Names: AR-1001Latest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator AriBio
- Class Anxiolytics; Erectile dysfunction therapies; Piperazines; Pyrimidinones; Small molecules; Sulfones
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Alzheimer's disease
- Phase I Dementia; Lewy body disease; Post-traumatic stress disorders; Stroke
- Preclinical Parkinson's disease
Most Recent Events
- 24 Mar 2024 AriBio licenses exclusive marketing rights of Mirodenafil to an Unknown company in China for Alzheimer’s disease
- 24 Mar 2024 Phase-III clinical trials in Alzheimer's disease in United Kingdom (PO) before March 2024 (NCT05531526)
- 25 Feb 2024 AriBio receives Notice of Acceptance from the MHRA for POLARIS-AD trial in Alzheimer's disease (PO)